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Cardiovascular diseases, including myocardial infarction (MI), represent the main
worldwide cause of mortality and morbidity. In this scenario, to contrast the
irreversible damages following MI, cardiac regeneration has emerged as a novel
and promising solution for in situ cellular regeneration, preserving cell behavior and
tissue cytoarchitecture. Among the huge variety of natural, synthetic, and hybrid
compounds used for tissue regeneration, alginate emerged as a good candidate
for cellular preservation and delivery, becoming one of the first biomaterial tested in
pre-clinical research and clinical trials concerning cardiovascular diseases. Although
promising results have been obtained, recellularization and revascularization of the
infarcted area present still major limitations. Therefore, the demand is rising for alginate
functionalization and its combination with molecules, factors, and drugs capable to
boost the regenerative potential of the cardiac tissue. The focus of this review is to
elucidate the promising properties of alginate and to highlight its benefits in clinical
trials in relation to cardiac regeneration. The definition of hydrogels, the alginate
characteristics, and recent biomedical applications are herewith described. Afterward,
the review examines in depth the ongoing developments to refine the material relevance
in cardiac recovery and regeneration after MI and presents current clinical trials based
on alginate.
Keywords: alginate, hydrogels, biomaterials, heart failure, cardiac regeneration, clinical trials
Abbreviations: ADSCs, adipose derived stem cells; CMs, cardiomyocytes; CVDs, cardiovascular diseases; ECs, endothelial
cells; ECM, extracellular matrix; EDD, end-diastolic dimension; EF, ejection fraction; ESD, end-systolic dimension; FDA,
Food and Drugs Administration; G, 1,4 α-L-guluronic acid; GRAS, generally regarded as safe; hMSCs, human mesenchymal
stem cells; LV, left ventricle; LVM, left ventricle mass; M, 1,4-linked β-D-mannuronic acid; MI, myocardial infarction; mPSCs,
mouse pluripotent stem cells; MSCs, mesenchymal stem cells; NCD, non-communicable disease; PSCs, pluripotent stem cells;
rMSCs, rat mesenchymal stem cells; VEGF, vascular endothelial growth factor; VSMCs, vascular smooth muscle cells.
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INTRODUCTION
The incidence of cardiovascular diseases (CVDs) accounts
for most of non-communicable disease (NCD) deaths
annually1 and has increased over the last few decades,
primarily because of the expansion of the “modern” lifestyle
in wealthy countries and the lengthening of life expectancy.
However, despite improvements in its management, CVDs
still remain the major cause of death worldwide claiming
17.9 million lives a year, with an estimated 31% of all
deaths globally.
Among CVDs, myocardial infarction (MI) remains one of
the leading cause of heart failure, which, in turns, represents
the commonest driver for mortality and morbidity (Cahill and
Kharbanda, 2017). At present, there is no definitive treatment
for MI, although great effort has been made to find new
therapies and permanent solutions (Mitter and Yancy, 2017).
The available treatments for MI and consequent heart failure
are drugs, medical electronic devices and, in the most severe
cases, heart transplants (Ferrini et al., 2019). One of the main
problems about infarcted heart is cardiomyocytes incapability
of self-regeneration along with lack of treatments able to
restore the lost parenchyma, thus the impossibility to reestablish
normal pump function. Regenerative medicine, combining tissue
engineering and drug delivery, aims to repair damaged or
diseased tissues and organs, and plays an important role in
restoring normal condition in the infarcted heart. Some evidence
showed that once applied onto MI, three dimensional printed
cardiac patches, and cardiac-tissue derived extracellular matrix
(ECM) scaffolds seem to have the potential to improve cardiac
functions, cardiac support, and tissue regeneration, improving
angiogenesis and reducing the scar size (Kc et al., 2019; Yeung
et al., 2019). The regenerative medicine approach can be cell-
free (Domenech et al., 2016; McLaughlin et al., 2019), or cell-
based, comprising stem cell therapy via injection or grafting
into the infarcted area, e.g., resident stem cells (Forrester
et al., 2003; Leor et al., 2007), myoblasts (Sekiya et al., 2009)
or by reprogramming fibroblasts directly into cardiomyocytes
(CMs) (Ieda et al., 2010). However, there are several intrinsic
limitations in restoring a complete and functional heart: (i)
cardiomyogenesis is very low and incapable to repair the
damaged areas (Zacchigna and Giacca, 2014; Leitolis et al.,
2019), and the infarcted area displays a hostile environment
for cells due to high level of oxidative stress, poor nutrient
supply, and it offers an open way for host immune system attack;
(ii) the recovery of the cardiac tissue requires maturation and
completeness in mechanical, electrical, and chemical function
(Pena et al., 2018); (iii) the majority of stem cells used for
therapeutic purposes in amending the infarcted heart are lost
within 1 day after the injection without using any vehicle-
matrix; (iv) the balance of cell-removal, ECM preservation, and
recellularization is challenging due to the residual presence of
detergent and endotoxin in the patch (Kc et al., 2019). Therefore
it emerges the necessity of looking for appropriate biomaterials
in a suitable form as cell preservation and delivery system (van
1https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases
den Akker et al., 2017; Weinberger et al., 2017; Zuppinger, 2019).
Biomaterials should provide biological, mechanical, electrical,
and chemical support for the myocardium and they should
mimic its physiological and homeostatic conditions (Pena et al.,
2018). Nowadays, the biomaterials that comprise cell-types and
scaffold properties are evolving (Foresti et al., 2019), as well
as the application strategies for these 3D artificial cardiac
tissues. Recently, thanks to novel hydrogel formulations and 3D
printing technology, it was possible to create ad hoc cardiac
patches (scaffold) for myocardial repair (Chachques et al.,
2020), drug or nanoparticles delivery (Bheri and Davis, 2019;
Foresti et al., 2020b) or injectable hydrogel for mechanical
stabilization of the repaired area (Seif-Naraghi et al., 2014;
Kambe and Yamaoka, 2019).
Hydrogels are a network of polymers of different origin:
natural, synthetic, or hybrid (a mix of natural and synthetic)
(Ye et al., 2011), extensively described and detailed classified by
Saludas et al. (2017) and Pena et al. (2018). Hydrogels have the
capability to absorb water, maintain their shape, and dissolve in
the body according to controlled kinetics Gauvin et al., 2012;
Saludas et al., 2017). One of the principal qualities of the hydrogel
is to be able to pass through a tiny syringe needle (27–30 G),
turning from liquid state at room temperature to gel-state in
the body at 37◦C (Sepantafar et al., 2016; Ferrini et al., 2019;
Milazzo et al., 2019).
Of note, hydrogels showed promising results in cardiac
regeneration in both preclinical models (Saludas et al.,
2017) and in some clinical trials as mechanical support in
the infarcted heart (Tous et al., 2011). Hydrogels give a
significant contribution to heart tissue regeneration being
capable of simulating a temporary artificial ECM (Saygili
et al., 2019) supporting cell infiltration, adhesion, proliferation,
and differentiation (Hasan et al., 2015). The most widely
used hydrogel (Lee and Mooney, 2012; Sun and Tan, 2013)
is the natural biomaterial alginate, which, together with
decellularized ECM [already extensively reviewed in Spinali’s
work, (Spinali and Schmuck, 2018)], represents the most
promising material in cardiac regeneration. Degradable and
bioactive microstructures of alginate-based hydrogel showed
a great promise on the recovery of left ventricular function as
well as the release of cardioactive substances (Hynes, 2009) in
the target tissue.
ALGINATE
Sodium alginate is a natural polymer found in brown algae
cell walls, including Macrocystis pyrifera, Laminaria hyperborea,
Ascophyllum nodosum (Sachan et al., 2009) and in several
bacteria strains (Azotobacter, Pseudomonas) (Remminghorst and
Rehm, 2006). Alginate’s hydrogels formed through physical
crosslinking present highly tunable mechanical properties (Hecht
and Srebnik, 2016), and thanks to its versatile and biological
properties alginate is widely used in biomedical research Cheng
et al., 2012; Ruvinov and Cohen, 2016; Saludas et al., 2017;
Dhamecha et al., 2019). In this section, we intend to provide a
brief insight into alginate characteristics.
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Chemical Properties
Alginate is an anionic polysaccharide. It is a linear copolymer
consisting of random sequences of 1,4-linked β-D-mannuronic
acid (M) and 1,4 α-L-guluronic acid (G) residues (Hecht and
Srebnik, 2016). Commercial alginate presents different ratios of
M and G residues and block-length depending on its source;
consequently, molecular weight (expressed as an average of
all the molecules in the sample) is variable and changes in a
range between 33,000 and 400,000 g/mol. Regarding polymer’s
solubility, it is important to underline that whereas alginic acid is
insoluble in water and organic solvents, alginate monovalent salts
and esters are water-soluble and form stable viscous solutions
(Szekalska et al., 2016).
Physical Properties
Alginate physical properties strictly depend on its composition
and concentration, which makes its characterization difficult,
but allows for a wide range of customization according to the
desired application (implantation, ECM mimic, etc.). An increase
of polymer concentration in the solution coincides with an
increase of gel stiffness, particularly when using high-molecular
weight alginates that maintain long-range interactions within
the gel (LeRoux et al., 1999). Nevertheless, increasing polymer
concentration also implies an increased viscosity of the pre-gelled
solution, which makes this strategy less feasible when cells or
active ingredients need to be included (Kong et al., 2003). In order
to modulate the stiffness without altering the viscosity, a possible
strategy is the combination of high and low-MW alginates in
specific ratios (Kong et al., 2002) or alternatively, the formation of
polyelectrolyte complexes through the addition of cationic poly-
(ethyleneimine) that increases the resistance to de-crosslinking
(Kong and Mooney, 2003).
Another relevant criterion that determines alginate physical
behavior is the crosslinking reaction. Many methods have been
described for alginate crosslinking, including ionic crosslinking,
covalent crosslinking, phase transition (thermal gelation), “click”
reaction, free radical polymerization (Sun and Tan, 2013) and
lowering the pH value below the pKa of alginate monomers
using lactones, such as d-glucono-δ-lactone (Sachan et al., 2009).
However, among these strategies, the most widespread is ionic
crosslinking since allows instantaneous and almost temperature-
independent solution/gel transition in relatively mild conditions,
in presence of multivalent cations, physical crosslinking is
instantaneous and almost temperature-independent.
Moreover, several studies revealed that, in presence of
divalent ions, alginate solution/gel transition occurred under
physiological conditions, such as the acidic environment of
the body fluids (Fu et al., 2011). In particular, many of the
technological applications of alginate rely on the gelation in
presence of Ca2+ in a two-step process that leads to the formation
of inter- and intra-chain bridging. Calcium ions interact with the
acidic sites on the G residues leading to chain-chain association;
following, the tightly linked dimers form weak interdimer
associations mainly governed by electrostatic interactions among
the dimers with higher Ca2+ concentration. This ion-chain
interaction involves the formation of a cage-shape association
of chain regions rich in G, implying that poly M-blocks and
alternating MG blocks display lower selectivity toward Ca2+
(Fu et al., 2011; Hecht and Srebnik, 2016). Therefore, gelling
properties depend not only on alginate molecular weight, but
are also strongly associated with its structure and composition
in terms of M-, G-, and MG-blocks (Sachan et al., 2009).
High G-blocks content determines low shrinkage during gel
formation and renders alginate stiffer, mechanically stable and
more permeable due to larger pores’ size (Martinsen et al.,
1989), while high M-blocks content are required when alginate
needs additional coating, such as enrichment of RGD sites to
mediate cell adhesion (Kuo and Ma, 2001; Niekraszewicz and
Niekraszewicz, 2009; Fu et al., 2011). Prevalence of MG-blocks,
instead, give rise to alginate shrinkage and higher flexibility
(Jorgensen et al., 2007; Szekalska et al., 2016).
Another relevant aspect to consider in the gelation process is
the velocity of the reaction. Slow gelation provides uniform and
ordered gel network structures with increased tensile properties
and mechanical integrity (Kuo and Ma, 2001; Drury et al.,
2004). One of the strategies to reduce the rate of gel forming
process is the application of phosphate buffers (e.g., sodium
hexametaphosphate); since the affinity of phosphate for calcium
is higher compare to that of alginate, the presence of phosphate
ions exert a chelating action and delay alginate gelation process
(Dainty et al., 1986; Xu et al., 2007) alternatively, is possible
to use calcium sulfate and calcium carbonate as Ca2+ sources:
the lower solubility of these reagents prolongs gel formation.
Lastly, another approach concerns the regulation of temperature:
at lower temperatures, the reactivity of Ca2+ is reduced and
allows the control of hydrogel formation (Augst et al., 2006;
Zhao Y. et al., 2016).
Mechanical Properties
Alginate-based hydrogel mechanical properties strictly depend
on the number and concentration of M and G residues (Augst
et al., 2006). If G overcomes M, the hydrogel displays high
mechanical stiffness. Therefore, by varying G and M content
it is possible to change the elastic modulus. It was observed
that elastic modulus homogeneity among 3D printing alginate-
based scaffolds strictly depends on the gelation rate (Mahdi et al.,
2016); slow processes result in greater homogenous scaffold (Kuo
and Ma, 2001). Kaklamani et al. (2014) demonstrated how the
gelation process can be modulated using divalent cations (Mg2+,
Ca2+, and Sr2+), resulting in a tight controlled Young modulus
of elasticity as a function of cations and alginate concentration.
Recently, it was demonstrated that xylitol, mannitol, or
peptides can modify the gelation process increasing strength
and elasticity (Ochbaum et al., 2018). The swelling properties
of alginate are also modulators of mechanical strength. Swelling
degree is inversely dependent on gelation time (bt Ibrahim et al.,
2019). Sodium alginate films immersed in CaCl2 solution for
2 min denote a swelling degree of 51% compared to those
immersed for 8 min (26%), suggesting that Ca2+ ions can
penetrate into the film matrix and interact with sodium ions
improving scaffold integrity and final geometry. In particular,
in order to increase the volume of a given bio-based device
it is necessary to increase the “surface-to-volume ratio” and
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engineering the structure (Elviri et al., 2017; Foresti et al., 2019)
by jellifying every single deposed layer (Campisi et al., 2018).
Finally, it becomes imperative to characterize the alginate
mechanical properties in light with the method of fabrication
(simple deposition/injection or scaffold manufacturing via 3D
printer) (Ozbolat and Hospodiuk, 2016) and for the final use as a
biomaterial (Ravnic et al., 2017).
Biological Properties
Alginate is regarded as biocompatible, non-immunogenic, and
non-toxic material (Sachan et al., 2009). Alginate cross-linked
gels are not degradable in mammalian digestive tract but the
elution of the multivalent ions eventually leads to its dissolution;
moreover, a physiological concentration of sodium ions has been
proved to alter alginate’s shear properties inducing a “softening
effect” on the hydrogel’s matrix (LeRoux et al., 1999). Alginate
biocompatibility was confirmed in vivo after ocular (Lin et al.,
2004), topical (Coskun et al., 2014), local (Veriter et al., 2010;
Chang et al., 2012), and oral administration (Sosnik, 2014).
Moreover, Food and Drug Administration has categorized several
alginate salts (calcium, sodium, ammonium, and potassium)
as well as propylene glycol alginate derivative as generally
regarded as safe (GRAS) ingredients for oral administration2
(Szekalska et al., 2016).
Besides being considered a safe polymer, alginate also
presents some properties that enhance its attractiveness
for biomedical applications, such as bio-adhesivity and
antibacterial/-viral activity.
The presence of free carboxyl groups provides good
mucoadhesive properties to alginate and allows its interaction
with mucin by hydrogen and electrostatic bonding (Hecht
and Srebnik, 2016; Szekalska et al., 2016). This property is
strongly influenced by environmental factors such as pH, since
only ionized carboxyl groups can interact with mucosal tissue.
Moreover, different soluble formulations of alginate facilitate
solvent penetration through its matrix, resulting in more viscous
and cohesive gel structures that strengthen the mucoadhesive
bonds; yet, an excessive hydration in physiological fluids might
weaken mucoadhesiveness as a results of attenuation of the
functional groups available for interactions (Taylor et al., 2005;
Mythri et al., 2011; Haugstad et al., 2015). Ionized carboxyl
groups also determine the reported antibacterial activity against
a wide variety of species, including Pseudomonas, Escherichia,
Proteus, and Acinetobacter (Khan et al., 2012; Pritchard et al.,
2016), negatively charged alginate interacts with the outer
bacterial cellular surface leading to its disruption (Yan et al.,
2011; Benavides et al., 2012). Furthermore, the formation of
a viscous layer around the bacterial cell prevents nutrient
transport, decreases membrane function (Yan et al., 2011),
and can exert chelation processes responsible for modulating
the production of toxins, microbial growth and other crucial
factors for microorganisms stability (Szekalska et al., 2016).
Alginate antiviral activity relies on sulfated polysaccharides
and alginic acid-containing fractions extracted from algae. The
2http://wayback.archive-it.org/7993/20171031063235/https://www.fda.gov/Food/
IngredientsPackagingLabeling/GRAS/SCOGS/ucm260857.htm
mechanism of action may be related to the strong anionic charge
of sulfated alginate, capable of interacting with the positively
charged host cell and, as a result, preventing virus contact
with the host cell (Witvrouw and De Clercq, 1997; Sano, 1999;
Meiyu et al., 2003). At present, antiviral efficacy has been
reported against Flaviviridae, Togaviridae, Rhabdoviridae, and
Herpesviridae viruses’ families (Son et al., 2003; Lee et al., 2011;
Wang et al., 2014; Ahmadi et al., 2015). Other relevant properties
concern the modulation of several responses to pathology,
from immunostimulation to anti-oxidant and anti-inflammatory
activities. It has been reported that alginate with high M-block
content is able to activate macrophages and monocytes leading
to the secretion of cytokines and cytotoxic factors (Son
et al., 2001). The anti-inflammatory cytokines secreted by
monocytes, eventually lead to attenuate the production of nitric
oxide, reactive oxygen species (ROS), prostaglandin E2, and
cyclooxygenase COX-2, determining therefore alginate anti-
oxidant effect (Rocha de Souza et al., 2007; Yamamoto et al., 2007;
Maciel et al., 2013; Namvar et al., 2013). Calcium alginate displays
hemostatic efficacy through platelets activation and thrombin
generation (Hattori et al., 2010), and it has been reported to
lower blood pressure as a results of calcium antagonist activity,
especially toward voltage-operated calcium channels (Chaki et al.,
2007; Terakado et al., 2012).
Alginate in Biomedical Research
Alginate due to its versatile and biologically properties such
as biocompatibility, (possible) non-immunogenicity, chelating
ability, water solubility, flexibility (it can be easily modified in any
form) and low-cost, is widely used in biomedical research (Sun
and Tan, 2013). In particular, alginate is used in protein/drug
delivery systems, tissue regeneration, and wound healing (Miao
et al., 2018). To date, there are several preclinical and clinical
studies (see paragraph below) using alginate as a cargo system to
control delivery bioactive agents, e.g., growth factors (Pawar and
Edgar, 2012), cytokines (Lee and Mooney, 2012), doxorubicin
(Paques et al., 2014), paclitaxel (Wu et al., 2014). Moreover,
alginate is also used as an excipient in several drugs due
to its gel forming, stabilizing and thickening properties, e.g.,
Gaviscon R©, Bisodol R©, Asilone (Miao et al., 2018). Regarding
tissue regeneration, unless big steps have been done, there is
still a considerable gap between research and clinical application
of alginate in tissue regeneration. More studies should be
performed in terms of improving alginate characterization,
functionalization, biodegradability, and mechanical properties
in order to facilitate tissue and organ regeneration. To date,
several studies have been done implying use of alginate in cardiac
regeneration (Rodness et al., 2016; Foresti et al., 2020a), skin
regeneration (Yang et al., 2019), osteo and cartilage regeneration
(Venkatesan et al., 2015; Calasans-Maia et al., 2019; Yang et al.,
2019), and neural tissue regeneration (Homaeigohar et al., 2019).
Due to its hydrophilicity, capability to adsorb wound exudate
and maintaining a moist microenvironment alginate is suitable
for wound dressing. Alginate dressings can be prepared by ionic
crosslinking (with calcium, magnesium, etc.) to form a gel, or
followed by processing to form freeze-dried porous sheets in form
of foams, and fibrous dressings (Aderibigbe and Buyana, 2018).
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At present, there are several alginate dressings commercially
available including AlgicellTM, FibracolTMPlus, Hyalogran R©,
and Tromboguard R©.
FUNCTIONALIZED ALGINATE
As mentioned in the introduction, the heart is a complex
electromechanical organ. After MI, it occurs loss of CMs,
lack of angiogenesis, and conductive connection disruption
that brings to a malfunctioned heart. Lack of treatments to
restore lost cardiomyocytes and cardiomyocytes incapability of
self-regeneration brought scientists to think about regenerative
medicine as a winner strategy to restore normal functionality
of the infarcted heart. Alginate emerged as a promising
natural polymer in cardiac regeneration, supporting heart
vascularization, re-cellularization, and restoring electrical
conductivity (Figure 1). In this section, it will be provided an
overview of alginate’s roles in restoring normal functionality
of infarcted heart; the studies took into consideration are
summarized in Table 1.
Alginate in Support of Heart
Vascularization
A crucial hurdle in the recovery post MI is lack of angiogenesis
that leads to the irreversible loss of cardiomyocytes in the first
2–4 h of the onset (Thygesen et al., 2007), thus contributing to
the progression of maladaptive ventricular remodeling, including
scar formation and ventricular dilatation, that can eventually
lead to heart failure (French and Kramer, 2007). To address this
deficiency in neovascularization both delivery of factors and/or
cells have been explored. Specifically, most works are focused
on delivering of mesenchymal stem cells (MSCs) and vascular
endothelial growth factor (VEGF). Beneficial effects of MSCs on
MI were already reported in literature (Gnecchi et al., 2008); their
impact was mainly related to an hypoxia-dependent secretion
of several cytokines, chemokines, and growth factors, that not
only exert a cytoprotective effect on cardiomyocytes survival
(Gnecchi et al., 2005), but lead also to an increase in collateral
perfusion through paracrine stimulation of proliferation and
migration of endothelial cells (ECs) and vascular smooth muscle
cells (VSMCs) (Kinnaird et al., 2004). Marrow-derived stromal
cells express genes encoding a broad spectrum of arteriogenic
cytokines and promote in vitro and in vivo arteriogenesis through
paracrine mechanisms (Nagaya et al., 2004). VEGF, instead, is
the most powerful and well-characterized proangiogenic cytokine
(Maharaj and D’Amore, 2007) associated with improvements
in cardiac vascularization (Oduk et al., 2018). Unfortunately,
delivery and retention of cells or growth factors to the damaged
area remains critical. Moreover, VEGF delivering may lead
to severe side effects, such as hypotension, limb edema, and
retinopathy, growth of tumors and/or metastasis (Zietz et al.,
1998; Baumgartner et al., 2000; Gasparini, 2000; Lee et al.,
2000; Freedman and Isner, 2002; Henry et al., 2003). Given
these considerations, it becomes clear why so much effort is
put into defining an appropriate cell or molecules delivery
system in order to help vascularization in the infarcted heart.
In this scenario, several studies demonstrated alginate suitability
as support material. Rodness et al. (2016) developed a VEGF-
loaded patch made of compacted alginate microspheres, retained
by a chitosan sheet. In order to combine alginate with the
growth factor, the authors mixed recombinant VEGF with Na+-
alginate solution and produced microspheres using a water-in-
oil-in-water double emulsion technique with pure olive oil and
ddH2O, and CaCl2 crosslinking; microspheres were following
compacted by centrifugation. From a certain point of view, this
strategy seems to recall and overcome the approach of current
clinical trials based on the mere injection of alginate in the
ventricular wall. The rationale behind this approach relies on
the highly tunable degradation of microspheres, that allows the
controlled release of pro-angiogenic factors, and the restraint
properties of a condensed microsphere patch reinforced with
chitosan. After assessing the biological activity of VEGF-loaded
patches in vitro, they were implanted on the epicardial surface
of a MI-rat model. Both VEGF-loaded and control patches
displayed similar functional outcomes in terms of fractional
shortening, cell infiltration, wall thickness, scar area and length,
to indicate that microsphere patch and chitosan sheet system may
function as a ventricular restraint device that limits the extent
of scar expansion post-MI. In addition, the team reported that
VEGF-loaded patches maintained their biological activity in vivo
up to 4 weeks after implantation, enhancing the spontaneous
angiogenesis and vasculogenesis within the compacted alginate
microspheres. An alternative approach to deliver VEGF to the
infarcted area was proposed by Liu et al. (2017), who investigated
the potential of MSCs as carriers of pro-angiogenetic factors. The
team took advantage of MSCs natural tropism to the infarcted
area (Lau and Wang, 2011) to deliver VEGF. They performed
a layer-by-layer (LbL) self-assembly coating where alginate
provided cohesion between two layers of gelatin embedded
with VEGF. This tiny-film fabrication technique consisted in
alternating steps of coating and washing, in which cells were
progressively incubated with gelatin, alginate and gelatin. This
strategy guarantees the maintenance of the metabolic activity
of the encapsulated material and endows protection (Yang
et al., 2011) without affecting cell viability, proliferation and
differentiation (Li et al., 2015). Other interesting approaches to
enhance vascularization involving cell delivery were successfully
tested on muscle tissue, paving the way to possible transitions
to the cardiac tissue. In the work of Nemati et al. (2017)
HUVECs were encapsulated in a mixture of gelatin and alginate
by the means of an electrostatic encapsulation method at high
voltage rate (8kV) followed by extrusion through a 26G needle
into a crosslinking solution of CaCl2. The composition of the
microcapsules allowed cell adhesion and migration through the
porous structures; furthermore, the authors observed, in vitro, an
increased production of NO combined with a high rate of cell
survival and an increased tubulogenic activity of encapsulated
HUVECs compared to control cells. The superior angiogenic
capability of encapsulated HUVECs was also confirmed in vivo
by injecting cell-laden microcapsules in the muscular tissue of
an immune-compromised mouse model. Whereas the direct
injection of HUVECs determined an extensive cell spread
resulting in the failure of microvascular formation, encapsulated
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FIGURE 1 | Alginate-based devices development in cardiac treatment. Alginate displays some physico-chemical and biological advantageous characteristics that,
combined together, render this biomaterial suitable for further modification. Possible modifications and implementations are: the inclusion of different cell types,
bioactive molecules, functional oligomers, and conductive materials to provide further functionalities to the pristine material addressing the main issues in cardiac
regeneration field. Thanks to its functionalization, alginate can be implied either as a delivery system or as a support material in cardiac regeneration choosing the
most efficient way of administration, in situ or not.
cells promoted an increase of vascular density constituted of
both large- and micro-size vascular structures with normal ECs
alignment and epithelialization in the periphery. Bushkalova
et al. (2019), instead, developed macroporous scaffolds made
of alginate-chitosan polyelectrolyte complexes to deliver MSCs
in soft tissues. This strategy exploits the association of alginate
with a cationic polymer, chitosan, to form a polyelectrolyte
complex of opposite charge that can be subsequently freeze-
dried and crosslinked; in this way, chemically unaltered polymers
preserve their initial biocompatibility while their rheological
properties improve and adapt to the mechanical resistance of
soft tissues. Instead of pursuing MSCs differentiation into a
specific cell type within the scaffold, the main goal of this work
was to ensure cells survival, retention, and paracrine activity in
order to stimulate the vascularization. In vitro tests assessed cell
viability and growth, besides an enhanced tendency to secrete
FGF2. The most promising results concern the in vivo model,
implantation in the pectoral muscle of healthy rats, where the
team found a good engraftment of the scaffold in the target
tissue within 28 days; the progressive degradation of the scaffold
was followed by the increasing formation of small functional
blood vessels and the reduction of the fibrous capsule. From
these studies, it emerged the real possibility of treating MI
through the combination of growth factors and a suitable cell
source to promote angiogenesis. Undoubtedly, further work
is needed to determine which cell source may be suitable in
clinical applications, in order to avoid immune-response or
off-target vascularization with consequent severe side effects
(Epstein et al., 2001).
Alginate in Cell Delivery Systems
After supporting vascularization of the infarcted area, the second
step is to repopulate the damaged area with cells. Mainly,
two different cell populations can be implanted, stem cells
that may form teratomas, or mature cardiomyocytes, which
can cause an electromechanical mismatch within the heart
(Chen et al., 2009; Liu et al., 2013). Recently, stem cell-based
therapies emerged as possible candidates in treating MI. Unless
many studies have been done, at present, only pluripotent
stem cells (PCSc) have shown clear ability to differentiate into
functional cardiomyocytes (Choe et al., 2019a). Furthermore,
cells retention in the heart is very low (Sanganalmath and
Bolli, 2013; Hirt et al., 2014); ischemic myocardium displays
a hostile environment for cells due to high level of oxidative
stress, poor nutrient supply and it offers an open way for host
immune system attack. Alginate hydrogels, porous scaffolds,



















TABLE 1 | Promising alginate-based systems in cardiac regeneration.
Material Factors Cell type Model Administration Treatment timing Monitoring time Results References










6 weeks Increased vascular density and
perfusion rate in the border zone;
restored indexes of ejection fraction
and fractional shortening.
Liu et al., 2017








1 week Increase of vascular density; endothelial
cell alignment; peripheral epithelization.
Nemati et al., 2017
Alginate-chitosan
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12 h after scaffold
hydration
1–4 weeks Good engraftment and gradual scaffold
degradation; functional blood vessels


















4 weeks Increased cell retention, survival and
migration into MI zone; improved
ejection fraction, stroke volume, cardiac
output and left ventricle end-systolic
and end-diastolic volumes; reduced
fibrosis ad hypertrophy.
Zhao S. et al., 2016










4 weeks Better fractional shortening; higher cell
infiltration and vascular-like structures;
increased scar thickness and










adjacent to MI area
Immediately after
myocardial injury
1–4 weeks Good electroactivity in vitro; increased
cell retention in vivo; improved ejection
fraction; decreased fibrotic area and
wall thinning; increased expression of
VEGF and Ang-1.










cultured for 3 days
3–8 days Increased cell alignment; higher levels
of proteins involved in contraction and
electrical coupling; synchronous
contraction and calcium transients in
temporal sequence.
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or alginate cell sheets/patches were enrolled to improve cell
retention, survival, and function in the ischemic heart. Despite
the continuous effort in developing less invasive procedures,
the evidence that alternative administration strategies, such
as intracoronary injection, may lead to a compromised cell
retention (Follin et al., 2018) drove most of the research toward
in situ application of the developed devices. Partially oxidized
alginate was used in preparing an ASDC-loaded conductive
H2S-releasing hydrogel system able to improve performances
of the infarcted zone in rats (Liang et al., 2019). Specifically,
alginate was oxidized through sodium iodate, and tetraaniline
(TA) and 2-aminopyridine-5-thiocarboxamide (APTC) were
employed to synthetize the multifunctional co-polymer; while
TA guaranteed conductive properties, APTC was responsible
for inflammatory response inhibition and angiogenic stimuli.
Moreover, in a recent in vitro study, alginate functionalized
with RGD sequence was employed to assess encapsulated
cells resistance to oxidative stress. The immobilization of the
RGD peptide to sodium alginate was performed utilizing the
aqueous carbodiimide chemistry (Shachar et al., 2011), thus
the peptide was conjugated to alginate via an amide bond
between its terminal amine and the carboxylate on alginate. The
results showed that human mesenchymal stem cells (hMSCs)
encapsulated in raw alginate or in alginate enriched with RGD
have higher resistance to hydrogen peroxide-induced cell death
(Choe et al., 2019b). Partially oxidized alginate was also employed
in a recent work where PSCs pre-differentiated into the early
cardiac lineage were encapsulated into an alginate-chitosan
micromatrix (ACM); to create the so-call micromatrix the
authors took advantage of the electrostatic interactions among
the positively charged chitosan and the negative charges of cell
membrane and alginate, by successively soaking cell aggregates
in the saline solution of the polymers. These aggregates were
injected into hearts of mice showing an increase in cardiac
function and survival of animals after MI (Zhao S. et al.,
2016). In addition to the previous challenges, another point
needs to be addressed, timing of stem cells injection; it was
showed that injection of SCs after 4–7 days from the MI
improves cells survival but, at the same time, significant injury
is accumulated in the ischemic heart (Suzuki et al., 2004; van
den Akker et al., 2013). Unless many steps should be done,
alginate cell-based therapy seems to be a promising way in the
treatment of MI.
Alginate in Restoring Electrical
Conductivity
The last aspect to be taken into consideration about restoring
the infarcted area is electrical conductivity. Alteration of the
normal cardiac conductive system, resulting in the interruption
of connectivity between ion channels and connexins (Huang
et al., 2017), is another evidence occurring after MI. CMs death
and scar tissue formation play a pivotal role in the conductive
connection disruption (Ongstad and Gourdie, 2016). The
development of a conductive injectable hydrogel can help
transmission of the electrical impulses and maintaining of a
stable cardiac rhythm, restoring the normal interchange between
the synchronous contractions and the relaxation time (Guo
and Ma, 2018). On the contrary, injection of non-electroactive
hydrogels, results in an electrically isolated system (Shin
et al., 2013), impeding the transmission of electrical impulses
to all the infarcted tissue and thus reducing the percentage
of success of the regenerative process. Natural hydrogels
represent convenient starting substrate to obtain electroactive
biomaterials; in particular, thanks to high water level retention,
good biocompatibility and their structural resemblance to ECM
that enables the diffusion of small molecules (Shi et al., 2016).
Moreover, hydrogels can be loaded with conductive components,
e.g., nanoparticles (NPs) such as gold nanoparticles (AuNPs),
carbon nanotubes (CNT), oligomers or conjugated with
conductive polymers, such as polypyrrole (PPy), polythiophene,
poly(3,4-ethylendioxythiophene (PEDOT), and Polyaniline
(PANi) (Shi et al., 2013; Huang et al., 2017). The main ways
to obtain conductive materials are, crosslinking between two
or more different materials (Zhang et al., 2014), chemical
oxidative in situ polymerization with an oxidant to start the
reaction (Shi et al., 2012), electrochemical polymerization
where hydrogels are used as conducting electrodes (Shi et al.,
2014), and post-polymerization/coating by two subsequently
hydrogel immersions, the first into monomer solution of
conductive polymer and, the second, into an oxidant solution
(Wu et al., 2015; Yang et al., 2016; Distler and Boccaccini,
2019; Jiang et al., 2019). Dvir et al. (2011) modified the
conductive properties of alginate through a calcium crosslinking
strategy incorporating gold nanowires (Alg–AuNW) obtaining
a patch where they seeded neonatal rat cardiomyocytes
and measured electrical conductivity. In particular, they
demonstrated an increased electrical conductivity of the
material itself and an increase of electrical conductivity of
seeded rat cardiomyocytes. Furthermore, they showed an
improvement in cell organization and contraction when the
length of gold nanowires surpass the thickness of alginate’s
pores (Dvir et al., 2011). Kaklamani et al. (2014) demonstrated
that alginate crosslinked with Ca2+ is more conductive than
alginate crosslinked with Sr2+; Sr2+ displays a larger ionic
radius compare to Ca2+, thus, it forms less ionic bridges
with alginate hydrogel compared to Ca2+. For instance, a
higher ions level is associated with larger charge density of the
hydrogel (Kaklamani et al., 2014). Alginate has also been used
for neural differentiation. The conductive hydrogel composed
with polypyrrole and alginate (PPy/Alg) has ten times more
electrical conductance compared to solely alginate hydrogel
(Yang et al., 2016; DeVolder et al., 2017; Ketabat et al., 2017;
Ren et al., 2019). The hybrid polymer is obtained by chemically
polymerizing PPy within ionically crosslinked alginate: pyrrole
monomers are allowed to diffuse into alginate hydrogels
before starting their polymerization with a chemical oxidant
(FeCl3); further stabilization is provided by the interactions
among positively charged pyrrole oligomers and negatively
charged alginate. PPy/Alg hydrogel promotes hMSC toward
a neural differentiation, implying a possible use for neural
tissue engineering (Yang et al., 2016). Interesting would be
the evaluation of the same PPy/Alg hydrogel in the contest
of cardiomyogenic maturity, or cardiovascular regeneration
Frontiers in Bioengineering and Biotechnology | www.frontiersin.org 8 May 2020 | Volume 8 | Article 414
fbioe-08-00414 May 7, 2020 Time: 22:5 # 9
Cattelan et al. Alginate in Cardiac Regeneration
therapy as well, since the conjugation of these two materials
provide an enhanced electrical conductivity, extremely necessary
for the cardiac regeneration.
Although great efforts have been put into developing
a conductive alginate, suitable to restore normal electrical
conductivity in infarcted heart, the way to reach this goal is
still very far. In order to restore a normal electromechanical
homeostasis within the myocardium the perfect material should
be capable to transmit electrical impulses with a proper
conduction velocity. Only recently, it emerged the importance
to study also the conductivity of injectable hydrogels for cardiac
regeneration. To conceive an ideal injectable alginate hydrogel
several strategies of manufacture should be combined together.
Only the implementation of alginate with cells, vascularization
factors and conductive elements would give a “complete material”
that can be used for cardiac therapy. The synergy of these





Food and Drugs Administration (FDA) approved alginate as
GRAS in food, pharma, and medicine (wound, bone) applications
already in 1970 (Frey et al., 2014; Lee et al., 2015). To date,
there are four clinical trials implying alginate in treating heart
failure; three of them are completed and the forth one is still
recruiting. Algisyl-LVRTM is the most used and commercially
available alginate hydrogel implied in sustaining the gradual
remodeling of the ventricle in patients subjected to dilated left
ventricle (LV), HF, and MI (Lee et al., 2013, 2015; Rao et al., 2016).
Until now, two clinical trials have been reported implying Algisyl-
LVRTM in restoring infarcted myocardium. Algisyl-LVRTM is
conjugated with calcium and sodium (furnished respectively in
an aqueous solution and insoluble particles in a 4.6% mannitol
solution), reaching a final strength of 3–5 kPa (Lee et al., 2015).
Algisyl-LVR is administered during a CABG procedure under
general anesthesia. After the intramyocardial injection, it changes
the status from liquid to gel remaining permanently in the human
heart. Algisyl-LVRTM showed no immune system reactions or
rejections, and, thanks to the ability to reduce cardiac tension and
cell stress, it enables the natural healing of the heart blocking the
disease progression.
SYM-08-001
The first clinical trial (NCT00847964) was published in 2015,
in which Algisyl-LVRTM was administered to 11 patients with
dilated cardiomyopathy underwent open-heart surgery with the
aim of left ventricular wall augmentation. Only nine patients
were able to complete the follow-up at day 8 and 3, 6, 12, 18,
and 24 months later, showing promising results. Amelioration
of LV size has been observed starting from the 3rd day after
the injection procedure. At the last time point of the follow-up
(24 months) no deaths occurred and the LV displayed a more
ellipsoidal shape with a reduction in the LV end-systolic and LV
end-diastolic dimension (LVESD–LVEDD) of respectively 9 and
12%. The ejection fraction (EF) improves of 28% over 24 months
while the myofiber stress at the end-of-diastole/systole decreased
for 35% over the same period. According to the New York
Heart Association (NYHA) classification, the patients’ life quality
improved showing a change to a less critical category for almost
all patients (II or III class) (Lee et al., 2015). Based on these results,
Algisyl-LVRTM has been considered feasible and safe for further
clinical trials.
AUGMENT-HF and AUGMENT-HF II
The second clinical trial performed using Algisyl-LVRTM was
AUGMENT-HF (N: NCT01311791). The study was conducted
in five different countries with a 1-year-follow-up, where Algisyl-
LVRTM was administered to 40 patients (plus 38 control patients
for a total number of 78 subjects) aged between 18 and 79 years
to modulate HF symptoms and improve heart functions (Anker
et al., 2015). After 6 months from injections, the patients showed
a progressive increase of the mean peak VO2 (the maximal
quantity of O2 in blood that the heart is able to provide to
muscles during a physical activity), while the six-minute walk
test (6MWT) increased above 300 m threshold for the treated
group but decreased in the control group. The 1-year-follow-
up demonstrated further enhancement both in mean peak VO2
and in 6MWT in treated group compared to control group,
where both conditions slightly worsen with time. These results
are correlated with a return to the physical activity for the
treated patients and the scaling up the NYHA functional class
(I or II) (Mann et al., 2016). An increase in LVEF (16%) was
observed after 12 months in the treated group, while LVEDD
and left ventricle mass (LVM) resulted decreased for a total of
4 and 9%, respectively (none of the parameters are statistically
significant but these findings are unexpected) (Mann et al., 2016).
It is possible to deduce that the treatment for HF patients
following the standard procedure with the additional Algisyl-
LVR injections is a functional strategy to treat HF patients.
This polymer lasts permanently in the heart bringing positive
effects to the cardiac health (LV augmentation and reduction
of LV stress) ameliorating the general mechanical support and
life quality of all the treated subjects. To date another clinical
trial is ongoing but not yet recruiting, AUGMENT-HF II
(NCT03082508). It consists of evaluating the efficacy and safety
of Algisyl in LV-augmentation and restoration in patients with
dilated cardiomyopathy.
PRESERVATION-1
Frey et al. (2014) administered in the pivotal study NCT01226563
the so-called hydrogel IK-5001 (BioLineRx, Jerusalem, Israel) to
27 patients (aged between 18 and 75 years) trying to prevent
or reverse left ventricular remodeling after a considerable MI
(severe-acute) within 7 days from the attack. No control group
is present in the study. IK-5001, an implantable bioabsorbable
cardiac matrix (BCM) device, is made of 1% sodium alginate
plus 0.3% calcium gluconate. IK-5001 hydrogel enters both in the
heart and in the extracellular space. Subsequently, it crosslinks



















TABLE 2 | Clinical trials using alginate as basic compound.
ID number Trial name Status Years Device Condition or
disease
Participants Description





11 A pilot study to evaluate the safety and
feasibility of Algisyl-LVR as a method of
left ventricular restoration in patients
with dilated cardiomyopathy
undergoing open-heart surgery (Lee
et al., 2015).
NCT01311791 AUGMENT-HF Completed August 2012–May
2016
Algisyl-LVR Heart failure; dilated
cardiomyopathy.
78 Randomized, controlled study to
evaluate the safety and cardiovascular
effects of Algisyl-LVR as a method of
left ventricular augmentation in patients
with dilated cardiomyopathy (Anker
et al., 2015; Mann et al., 2016).
NCT03082508 AUGMENT -HFII Not yet recruiting Estimated August
2017–January
2024





Estimated 240 A pivotal trial to establish the efficacy
and safety of Algisyl-LVR in patients
with moderate to severe heart failure1.









303 A placebo controlled, multicenter,
randomized double blind trial to
evaluate the safety and effectiveness of
IK-5001 for remodeling prevention of
the ventricle and congestive heart
failure after acute myocardial infarction
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in a gel solution thanks to high ionized calcium concentration
(characteristic of infarcted myocardium), creating a cardiac
scaffold resembling ECM that is bioabsorbable by the tissue
and is discarded by kidneys in 3–6 months after the injection
(Rao et al., 2015, 2016). In parallel, in the animal model was
shown that BCM reabsorption was followed and substituted
by a network of capillaries, myofibroblasts and collagen fibrils
(Sabbah et al., 2013; Ruvinov and Cohen, 2016). The subjects
were controlled after 30, 90, and 180 days from the injections.
No further myocardial damages, arrhythmias were observed
(Frey et al., 2014). LV remodeling appeared mild recovered with
a conservation of LV end-diastolic/end-systolic volume index
(LVEDVI – LVESVI) and LVEF parameters. No adverse or serious
events have been proven to be correlated with the injections; there
was only one episode of syncope after 172 days of administration
correlated with the treatment. The whole procedure was well
tolerated by patients; in addition, the injections were performed
under local anesthesia via percutaneous radial artery access and
not undergoing an open-heart surgery under general anesthesia
(Frey et al., 2014). This pilot study opened the window on a
consecutive bigger clinical trial called PRESERVATION-1 (nr:
NCT01226563) with the aim to prevent, after one severe MI,
ventricle remodeling and heart failure congestion (congestive
HF). Two hundred and one subjects were treated with IK-5001
and were compared with 102 healthy subjects. After 6 months,
no significant results were obtained. LVEDVI and adverse events
remained constant and similar between the two groups. No
significant differences have been detected in the improvement
of the 6MWT for the treated group; however, a positive and
beneficial trend has been shown in the treated group. Severe
adverse effects appear to be more frequent in treated subjects
(5%) compared to control group (2.9%), on the contrary low
rate of mortality and MI have been detected in the treated group
compared to the control group. Given these results, neither
impressive anatomical changes, nor progress of life quality has
been demonstrated in MI subjects. It can be assumed that some
results might be linked to the severe MI symptoms that affected
some patients that, due to the severity of the damages, could not
be treated (Rao et al., 2016).
So far, clinical trials demonstrated the feasibility and safety
of treating MI with alginate. Nevertheless, is still necessary
to identify the most suitable administration route to exert a
therapeutic effect. Indeed, whereas the IK-5001 strategy has
the appealing of providing a less-invasive administration, the
lack of significant results and life-quality improvements in
PRESERVATION-1 trial may indicate a poor specificity for the
target area. The direct injection of Algisyl-LVRTM prevents this
issue but at the same time underlines the passive role of the
biomaterial, whose therapeutic effects seems to rely on providing
physical support to the weakened area. Table 2 summarized the
discussed clinical trials.
CONCLUSION
Cardiovascular diseases are the number one cause of death
globally. In particular, acute MI, according to WHO, causes
7.3 million deaths worldwide. Despite great strides have been
done in the last decade prognosis is still unfavorable, and
the search to find new and innovative treatments to heal the
infarcted heart is still open. Recently, cardiac regeneration
emerged as a promising solution to restore injured heart.
The heart is a complex, conductive, and electromechanical
organ, thus the necessity to find a durable and conductive
material to resist and persist in the “harsh infarcted heart
environment.” To date, there are no hydrogels able to mimic
cardiac tissue. However, alginate, among all the biomaterials
available, seems to be a good candidate for cardiac regeneration.
On one hand alginate is a natural polymer, biodegradable,
biocompatible, and already approved by FDA for human
purposes; moreover, it can be easily modified, it is versatile,
and it has affordable production costs. On the other hand,
alginate contains many impurities and it is highly hydrophilic.
Available results from clinical trials in patients showed that
alginate only mildly ameliorates some cardiac parameters
but seems to improve patient’s quality of life. To be noted
that, until now, all these trials have been focused on the
injection of pristine alginate in the damaged area. Despite
promising results, so far, no experimentation provided a decisive
outcome. Although data from literature show encouraging
results, improving vascularization and cell retention in the
infarcted area, in a clinical context their potential is limited to
temporary solutions and does not show deep ameliorates. To
date, all clinical trials imply alginate as mechanical support of
the infarcted area, thus the possible premature degradation of
alginate inside the organism, in parallel with the incapability
of the resident cardiomyocytes to regenerate the infarcted area
and the failure in restoring a proper cardiac conductivity,
could be the reasons of the partial outcome of the clinical
trials. In order to overcome this issue could be useful to
complete the stage of cellularization of the alginate matrix
in vitro with cardiomyocytes; nevertheless, it is well known
the difficulty of handling mature cardiomyocytes in vitro and
the ethical limitations. Moreover, particular attention should
be paid to electrical conductivity to prevent arrhythmias,
both inserting an alginate matrix capable of substitute the
infarcted area and transmit the electrical signal or guiding
the cardiomyocytes within the scaffold avoiding spontaneous
beating activity. Furthermore, it is necessary to know better
the mechanisms underneath the remodeling occurring in the
infarcted heart in order to establish when, where, and how
much material to inject. So far, the use of alginate in cardiac
regeneration seems to be promising, even though a deeper
characterization is needed for the eventual translation to
the clinical field.
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